~~<i id='1533B22E49'><strike id='1533B22E49'><tt id='1533B22E49'><pre id='1533B22E49'></pre></tt></strike></i>~~

Home» Wikipedia» leisure time

leisure time

author：focus 2025-10-09 00:18:47 Page View：467

Damian Garde of STAT talks with Liisa Bayko of Evercore ISI and Jared Holz of Mizuho at STAT in NYC. — Damian Garde of STAT, left, talked with Liisa Bayko of Evercore ISI and Jared Holz of Mizuho about the GLP-1 weight loss market. Michelle C. Gevint for STAT

NEW YORK — Will the world actually soon spend $100 billion a year on the new obesity medicines?

Plenty of people in pharma and at the banks that invest in it seem to think so. Goldman Sachs, Barclays, BMO Capital Markets and Pfizer have all arrived at the glossy, cut-for-headline number for spending by around 2030.

Yet Jared Holz, a healthcare strategist at Mizuho, is skeptical.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Cosmetics set for new safety regulation. Why the industry is on board
Next article： At least 13 dead in Texas as scorching temps continue

explore

The cancer drug shortage isn’t new — and neither are the solutions

PreparingachemotherapytreatmentatDukeCancerCenterinDurham,N.C.GerryBroome/APAyounggirl,maybe5or6year

EHR maker NextGen Healthcare to pay $31M to resolve fraud claims

AdobeThehealthrecordscompanyNextGenHealthcarewillpay$31milliontoresolveallegationsthatitpaidkickback

Trump demands the U.S. pay no more for drugs than other countries … again

EthanMiller/GettyImagesWASHINGTON—FormerPresidentTrumpisbacktocampaigningfortyingMedicaredrugpricest

Cosmetics set for new safety regulation. Why the industry is on board

AlbertoPellaschiar/APWASHINGTON—ForthosealreadyfelledbyfumesfromtheBrazilianBlowout,itmightbesmallco